Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Immunohorizons. 2018 Jan 1;2(1):54–66. doi: 10.4049/immunohorizons.1700069

FIGURE 1. MR1-TM inhibits the development of severe ATD and pSS in CD28−/− NOD.H-2h4 mice.

FIGURE 1

(A) Mice (both sexes) were given 400 μg of MR1-TM or isotype control at 5–6 wk of age. The next day, they were given NaI-supplemented water, and thyroids were removed 7–8 wk later. Each point represents an individual mouse given isotype control or MR1. Female: n = 16, male: n = 10. ****p < 0.0001. (B) Representative H&E-stained sections of thyroids from a mouse given isotype control or MR1 (original magnification ×100). Scale bar, 10 μM. (C) Serum T4 levels in some mice from (A). Values less than or equal to three indicate low thyroid function (see Materials and Methods). ****p < 0.0001. (D) Salivary gland infiltration of some mice in (A). Each point represents the focus score of an individual mouse (n = 11 for each group). **p < 0.001 Iso versus MR1, for females and males. Females have significantly higher focus scores than males (*p < 0.05). (E) Representative H&E-stained and immunohistochemistry-stained sections (B cells, red; T cells, green) of a salivary gland from a female mouse given isotype control and a female mouse given MR1. Mice are 4 mo old. Original magnification ×100 (immunohistochemistry). Scale bar (H&E), 1 mm.